Five patients with CML-BP and two with de novo BCR::ABL1+AML who did not receive intensive chemotherapy were excluded from the analysis of treatment response and outcome. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.